Skip to main content

Table 1 Baseline characteristics of type 2 diabetes mellitus (T2DM) patients divided according to the cardiovascular death

From: Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long‐term follow‐up study

Variable Non-survivors (n = 16) Survivors (n = 117) p-value
Age, years 70.5 (64.0–77.0) 65.0 (60.0–71.0) 0.09
Female gender, n (%) 5 (31.3) 49 (41.9) 0.59
Current smoking, n (%) 2 (12.5) 10 (8.6) 0.64
Body-mass index, kg/m2 31.4 (26.2–34.2) 31.6 (28.4–35.4) 0.34
Obesity, n (%) 10 (62.5) 80 (68.4) 0.78
Time since T2DM diagnosis, years 8.0 (2.0–13.0) 5.0 (2.0–10.0) 0.43
Comorbidities, n (%)
 Arterial hypertension 14 (87.5) 112 (95.7) 0.20
 Coronary artery disease 13 (62.3) 73 (62.4) 0.17
 Previous myocardial infarction 6 (37.5) 19 (16.2) 0.08
 Previous stroke 3 (18.8) 4 (3.4) 0.04
 Nephropathy 6 (37.5) 17 (14.5) 0.03
 Neuropathy 4 (25.0) 20 (17.1) 0.49
 Retinopathy 4 (25.0) 17 (14.5) 0.28
Medications, n (%)
 Acetylsalicylic acid 13 (81.3) 92 (78.6) 1.00
 Statin 13 (81.3) 93 (79.5) 1.00
 ACE-I 10 (62.5) 81 (69.2) 0.58
 β-blocker 14 (87.5) 91 (77.8) 0.52
 Metformin 5 (31.3) 75 (64.1) 0.02
 Sulfonylourea 9 (56.3) 47 (40.2) 0.28
 Insulin 6 (37.5) 27 (23.1) 0.23
  1. Continuous data are presented as the median (interquartile range) and compared using Mann–Whitney test. Categorical data are presented as number (percentages) and compared using Fisher’s exact test
  2. ACEI angiotensin converting enzyme inhibitor